Recent animal studies have shown that the genetic deletion of IL-10 exacerbates obesity-induced atrial inflammation, fibrosis, and fibrillation and that IL-10 therapy can inhibit this pathology [67]. This evidence concerns the gene IL10 and obesity disorder.